An assessment of the performance of self-reported vaccination status for Hepatitis B, National Health and Nutrition Examination Survey 1999-2008

American Journal of Public Health

Volumn 103, Issue 10, 2013, Pages 1865-1873

  Denniston, Maxine M ^a   Byrd, Kathy K ^b   Klevens, R Monina ^a   Drobeniuc, Jan ^c   Kamili, Saleem ^c   Jiles, Ruth B ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Prevention Branch   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CHILD; CONFIDENCE INTERVAL; FEMALE; HEALTH SURVEY; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOLOGY; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PRESCHOOL CHILD; SELF REPORT; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; FEMALE; GUIDELINE ADHERENCE; HEALTH SURVEYS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; LOGISTIC MODELS; MALE; MIDDLE AGED; SELF REPORT; YOUNG ADULT;

EID: 84884146474     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2013.301313     Document Type: Article

References (17)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12): 2212-2219.
2. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4): 271-278.
3. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202: 192-201.
4. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep. 1991;40(RR-13): 1-19.
5. Ramsay ME, Rushdy AA, Harris HE. Surveillance of hepatitis B: an example of a vaccine preventable disease. Vaccine. 1998;16:S76-S80.
6. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9): 1390-1396.
7. Shenson D, Dimartino D, Bolen J, et al. Validation of self-reported pneumococcal vaccination in behavioral risk factor surveillance surveys: experience from the sickness prevention achieved through regional collaboration (SPARC) program. Vaccine. 2005;23(8): 1015-1020.
8. Mac Donald R, Baken L, Nelson A, Nichol KL. Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med. 1999;16(3): 173-177.
9. SUDAAN Language Manual, Release 10.0. Research Triangle Park, NC: Research Triangle Institute; 2008.
10. Gordon NP, Wortley PM, Singleton JA, Lin TY, Bardenheier BH. Race/ethnicity and validity of selfreported pneumococcal vaccination. BMC Public Health. 2008;8: 227.
11. Tawk HM, Vickery K, Bisset L, Selby W, Cossart YE; Infection in Endoscopy Study Group. The impact of hepatitis B vaccination in a Western country: recall of vaccination and serological status in Australian adults. Vaccine. 2006;24(8): 1095-1106.
12. Guide to Community Preventive Services. Universally recommended vaccinations: immunization information systems. 2010. Available at: http://www. thecommunityguide.org/vaccines/universally/imminfosystems.html. Accessed May 16, 2011.
13. Spradling PR, Williams RF, Xing J, Soyemi K, Towers J. Serological testing for protection against Hepatitis B virus infection among students in a health sciences university in the United States. Infect Control Hosp Epidemiol. 2012;33(7): 732-736.
14. Tohme RA, Ribner B, Huey MJ, Spradling PR. Hepatitis B vaccination coverage and documented seroprotection among matriculating healthcare students at an academic institution in the United States. Infect Control Hosp Epidemiol. 2011;32(8): 818-821.
15. Ayerbe MC, Perez-Rivilla A, ICOVAHB group. Assessment of long-term efficacy of hepatitis B vaccine. Eur J Epidemiol. 2001;17: 151-156.
16. Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after Hepatitis B vaccination. J Hepatol. 1988;6: 201-207.
17. Wood RC, MacDonald KL, White KE, et al. Risk factors for lack of detectable antibody following Hepatitis B vaccination of Minnesota health care workers. JAMA. 1993;270(24): 2935-2939.